Compare ROIV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | ILMN |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 20.4B |
| IPO Year | 2021 | 2000 |
| Metric | ROIV | ILMN |
|---|---|---|
| Price | $28.58 | $124.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 17 |
| Target Price | $27.56 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 6.3M | 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 5.45 |
| Revenue | $29,053,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | N/A | $6.52 |
| Revenue Next Year | $385.85 | $5.49 |
| P/E Ratio | ★ N/A | $23.52 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $68.70 |
| 52 Week High | $30.03 | $155.53 |
| Indicator | ROIV | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 44.37 |
| Support Level | $20.46 | $124.27 |
| Resistance Level | N/A | $126.00 |
| Average True Range (ATR) | 0.95 | 4.36 |
| MACD | -0.00 | 1.22 |
| Stochastic Oscillator | 66.80 | 49.94 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.